ライフサイエンスコーパス: transcription activator-like effector

1 Gene induction is mediated by a type III transcription activator-like effector.

2 enome engineering that can be achieved using transcription activator-like effectors.

3 Moreover, we developed a multiplex transcription activator-like effector activation (mTALE-

4 able across Type I, II and V CRISPR systems, transcription activator-like effectors and zinc finger p

5 Transcription activator-like effectors are sequence-spec

6 Fusions of the split-DddA halves, transcription activator-like effector array proteins, an

7 Here, we show that the Xhg transcription activator-like effector AvrHah1 is both ne

8 o some extent, little data are available for transcription activator-like effector-based nucleases (T

9 ng meganucleases, zinc finger nucleases, and transcription activator-like effector-based nucleases.

10 We directionally inserted 2 distinct transcription activator-like effector binding elements i

11 nd DNA, outperforms zinc-finger proteins and transcription activator-like effectors, both of which ta

12 dei isolates, a phenomenon also observed for transcription activator-like effector-dependent genes kn

13 ed artificial DNA looping driven by designed transcription activator-like effector dimer (TALED) prot

14 ystems based on target sequence-programmable Transcription Activator-Like Effector dimer (TALED) prot

15 ive piggyBac constructs tethered to a custom transcription activator like effector DNA-binding domain

16 Fusion with transcription activator-like effector DNA binding domain

17 These molecular tools are fusions of transcription activator-like effector domains (TALE) for

18 this study, we use an artificially designed transcription activator-like effector (dTALE) to activat

19 TAL (transcription activator-like) effectors from Xanthomonas

20 ins a greater number of virulence-associated transcription activator-like effector genes and has at l

21 Recently, meganucleases fused to transcription activator-like effectors have been demonst

22 Transcription activator-like effectors have enabled the

23 Transcription activator-like effector nuclease (TALEN) a

24 Here we report that transcription activator-like effector nuclease (TALEN) a

25 Here we use transcription activator-like effector nuclease (TALEN) a

26 stem to: (1) computationally identify unique transcription activator-like effector nuclease (TALEN) b

27 elper-dependent adenoviral vector (HDAdV) or Transcription Activator-Like Effector Nuclease (TALEN) e

28 Transcription activator-like effector nuclease (TALEN) i

29 Here we show that electroporation of transcription activator-like effector nuclease (TALEN) m

30 receptor (GR) gene using electroporation of transcription activator-like effector nuclease (TALEN) m

31 elopment, we have generated a Dot1L-specific transcription activator-like effector nuclease (TALEN) n

32 eated a new NKT-deficient mouse strain using transcription activator-like effector nuclease (TALEN) t

33 ne targeting, zinc-finger nuclease (ZFN) and transcription activator-like effector nuclease (TALEN) t

34 ta-Thal iPSCs from the cells of patients and transcription activator-like effector nuclease (TALEN)-b

35 ents in CRPC tissues, which we modeled using transcription activator-like effector nuclease (TALEN)-m

36 We used transcription activator-like effector nuclease (TALEN)-m

37 umab have previously been investigated using transcription activator-like effector nuclease (TALEN)-m

38 By using transcription activator-like effector nuclease (TALEN)-m

39 Zinc-finger nuclease, transcription activator-like effector nuclease and CRISP

40 , catalytically dead Cas9 fused to FokI, and transcription activator-like effector nuclease at three

41 By using the transcription activator-like effector nuclease gene edit

42 ere detected at sites of DNA DSBs induced by transcription activator-like effector nuclease proteins.

43 In addition, using the recently developed transcription activator-like effector nuclease technolog

44 nerated an RP2 knockout zebrafish line using transcription activator-like effector nuclease technolog

45 In this study, we used transcription activator-like effector nuclease technolog

46 A transcription activator-like effector nuclease was desig

47 Transcription activator-like effector nuclease-based kno

48 imary human T cells using a combination of a transcription activator-like effector nuclease-induced d

49 ated a mouse model of Fndc5 mutation through transcription activator-like effector nuclease-mediated

50 PDE12-null cell line, HeLaDeltaPDE12, using transcription activator-like effector nuclease-mediated

51 In conclusion, transcription activator-like effector nuclease-mediated

52 We applied transcription activator-like effector nuclease-mediated

53 Transcription activator-like effector nucleases (TALEN)

54 Transcription activator-like effector nucleases (TALEN)

55 Injection of transcription activator-like effector nucleases (TALEN)

56 (CAR) Tcells containing gene edits made with transcription activator-like effector nucleases (TALEN).

57 Recently, transcription activator-like effector nucleases (TALENs)

58 for HIV research (293T and Jurkat), we used transcription activator-like effector nucleases (TALENs)

59 Zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs)

60 Transcription activator-like effector nucleases (TALENs)

61 of mouse disease models by microinjection of transcription activator-like effector nucleases (TALENs)

62 Transcription activator-like effector nucleases (TALENs)

63 Transcription activator-like effector nucleases (TALENs)

64 We have engineered transcription activator-like effector nucleases (TALENs)

65 A pair of zinc finger nucleases (ZFNs) or transcription activator-like effector nucleases (TALENs)

66 Zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs)

67 Transcription activator-like effector nucleases (TALENs)

68 Transcription Activator-Like Effector Nucleases (TALENs)

69 Transcription activator-like effector nucleases (TALENs)

70 Transcription activator-like effector nucleases (TALENs)

71 Here we show that improvements in artificial transcription activator-like effector nucleases (TALENs)

72 A to a model problem, construction of custom transcription activator-like effector nucleases (TALENs)

73 Engineered transcription activator-like effector nucleases (TALENs)

74 Here we engineered transcription activator-like effector nucleases (TALENs)

75 ategy using zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs)

76 lving, from the early zinc-finger nucleases, transcription activator-like effector nucleases (TALENs)

77 development of zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs)

78 Here, using mitochondrial-targeted transcription activator-like effector nucleases (TALENs)

79 In this study, mRNAs encoding transcription activator-like effector nucleases (TALENs)

80 sferase-directed sequence-specific labeling, transcription activator-like effector nucleases (TALENs)

81 en enabled by programmable nucleases such as transcription activator-like effector nucleases (TALENs)

82 Our reagents, based on transcription activator-like effector nucleases (TALENs)

83 ndromic repeats-CRISPR-associated 9) system, transcription activator-like effector nucleases (TALENs)

84 neering using programmable nucleases such as transcription activator-like effector nucleases (TALENs)

85 e-specific DNA double strand breaker, either transcription activator-like effector nucleases (TALENs)

86 Transcription activator-like effector nucleases (TALENs)

87 y optimized zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs)

88 Transcription activator-like effector nucleases (TALENs)

89 d success of site-specific nucleases such as transcription activator-like effector nucleases (TALENs)

90 nge the LGB sequence, we co-injected ZFNs or transcription activator-like effector nucleases (TALENs)

91 Gene correction using transcription activator-like effector nucleases (TALENs)

92 at disruption of the BmOR1 gene, mediated by transcription activator-like effector nucleases (TALENs)

93 lly targeting E6 and E7 within host DNA with transcription activator-like effector nucleases (TALENs)

94 eases, like zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs)

95 ng of wild-type iPSCs using a combination of transcription activator-like effector nucleases (TALENs)

96 Although transcription activator-like effector nucleases (TALENs)

97 vage reagents: zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs)

98 aced Short Palindromic Repeats (CRISPRs) and Transcription Activator-Like Effector Nucleases (TALENs)

99 Transcription activator-like effector nucleases (TALENs)

100 Recent gene-editing tools, such as transcription activator-like effector nucleases and clus

101 different loss-of-function approaches using transcription activator-like effector nucleases and morp

102 otential off-target sites for newly designed transcription activator-like effector nucleases containi

103 f zebrafish f10 by using genome editing with transcription activator-like effector nucleases results

104 We detected cleavage by two out of three transcription activator-like effector nucleases that we

105 we generated Rac2-deficient zebrafish using transcription activator-like effector nucleases to direc

106 CYP71A12-specific transcription activator-like effector nucleases were int

107 ing techniques such as zinc-finger proteins, transcription activator-like effector nucleases, and CRI

108 e-specific nucleases (zinc-finger nucleases, transcription activator-like effector nucleases, and the

109 nucleases, such as zinc finger nucleases and transcription activator-like effector nucleases, and to

110 Gene editing with zinc finger nucleases, transcription activator-like effector nucleases, cluster

111 ting tools, including zinc finger nucleases, transcription activator-like effector nucleases, cluster

112 lation of the genome (zinc finger nucleases, transcription activator-like effector nucleases, or clus

113 ose obtained using zinc finger nucleases and transcription activator-like effector nucleases.

114 correction of the common G691A mutation with transcription activator-like effector nucleases.

115 rammable sequence-specific nucleases such as Transcription Activator-Like Effectors Nucleases (TALENs

116 We used this system to generate transcription activator-like effectors nucleases (TALENs

117 The newly developed transcription activator-like effector protein (TALE) and

118 t targeted demethylation of the ICR2 using a transcription activator-like effector protein fused to t

119 subunit in defective cells and CRISPR-Cas9, transcription activator-like effector protein nuclease,

120 engineered zinc finger proteins (ZFP), four transcription activator-like effector proteins (TALE), C

121 Transcription activator-like effector proteins (TALEs) c

122 n CsCyp is a target of the Xanthomonas citri transcription activator-like effector PthA, required to

123 ecificity, and the DNA-binding domain of the transcription activator-like effector, TAL.

124 However, the transcription activator-like effector (TALE) associated

125 Within the past 2 years, transcription activator-like effector (TALE) DNA binding

126 trate the use of comprehensive and versatile transcription activator-like effector (TALE) libraries.

127 th DNA binding proteins, zinc fingers (ZFs), transcription activator-like effector (TALE) modules, an

128 ategy to investigate the cryptic role of the transcription activator-like effector (tale) multigene f

129 use it allows sequence-specific DNA binding, transcription activator-like effector (TALE) offers a ne

130 ctural proteins based on a sequence-specific Transcription Activator-like Effector (TALE) protein, ei

131 yltransferase to DNA or through binding of a transcription activator-like effector (TALE) protein.

132 Transcription activator-like effector (TALE) proteins ar

133 Transcription activator-like effector (TALE) proteins ca

134 The discovery of a novel type of DBD in transcription activator-like effector (TALE) proteins fr

135 rategy for generating such reagents based on transcription activator-like effector (TALE) proteins fr

136 paced short palindromic repeats (CRISPR) and transcription activator-like effector (TALE) proteins ha

137 Transcription activator-like effector (TALE) proteins ha

138 Transcription activator-like effector (TALE) proteins of

139 Transcription activator-like effector (TALE) proteins re

140 eport a modular system based on programmable transcription activator-like effector (TALE) proteins, w

141 s in human cells using fusions of engineered transcription activator-like effector (TALE) repeat arra

142 yme to a site-specific DNA binding domain of transcription activator-like effector (TALE) resulted in

143 Artificial activators designed using transcription activator-like effector (TALE) technology

144 However, the transcription activator-like effector (TALE)-associated

145 We describe a transcription activator-like effector (TALE)-based strat

146 Induction of SWEET sugar transporters by Transcription Activator-Like effectors (TALe) of Xanthom

147 ed by the matching Xanthomonas euvesicatoria transcription-activator-like effector (TALE) AvrBs3.

148 ntral methods, zinc finger nucleases (ZFNs), transcription activator-like effectors (TALENs), and CRI

149 g platforms, including zinc finger proteins, transcription activator-like effectors (TALEs) and the c

150 The transcription activator-like effectors (TALEs) and the R

151 Transcription activator-like effectors (TALEs) are a cla

152 Transcription activator-like effectors (TALEs) are a cla

153 Transcription activator-like effectors (TALEs) are a nov

154 Transcription activator-like effectors (TALEs) are bacte

155 Transcription activator-like effectors (TALEs) are virul

156 Transcription activator-like effectors (TALEs) bind DNA

157 Transcription activator-like effectors (TALEs) can be us

158 Transcription activator-like effectors (TALEs) contain m

159 We tested whether transcription activator-like effectors (TALEs) could med

160 Transcription activator-like effectors (TALEs) from the

161 Transcription activator-like effectors (TALEs) from Xant

162 Transcription activator-like effectors (TALEs) have revo

163 Bacterial transcription activator-like effectors (TALEs) promote p

164 Transcription activator-like effectors (TALEs) recognize

165 ic bacteria of the genus Xanthomonas possess transcription activator-like effectors (TALEs) that acti

166 equence-specific nucleases created by fusing transcription activator-like effectors (TALEs) to the ca

167 ous genomic loci in live cells by the use of transcription activator-like effectors (TALEs), as well

168 enced genes, with combinations of engineered transcription activator-like effectors (TALEs).

169 DNA methyltransferases (DNMTs) to engineered transcription activator-like effectors (TALEs).

170 Transcription-activator-like effectors (TALEs) are repea

171 This is enabled by the use of engineered transcription-activator-like effectors (TALEs) as DNA ma

172 We report engineered, programmable transcription-activator-like effectors (TALEs) as the fi

173 zae (Xoo), secretes one or more of six known transcription-activator-like effectors (TALes) that bind

174 Transcription-activator-like effectors (TALEs), an effec

175 zae, which utilizes a group of type III TAL (transcription activator-like) effectors to induce host g

176 Here we report two improvements of the transcription activator-like effector toolbox for achiev

177 We also report an effective transcription activator-like effector transcriptional re

178 uch as type III secreted effectors including transcription activator-like effectors, type II secretio